problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl12778problendo-12778Research ArticleРедакционная статьяEditorialРоль конечных продуктов гликирования в развитии и прогрессировании диабетической нейроостеоартропатииThe role of glycation end products in the development and progression of diabetic neuroarthropathyhttps://orcid.org/0000-0001-9422-2111КаландияМ. М.KalandiyaM. M.

Каландия Мария Малхазовна – аспирант.

117036, Москва, ул. Дм. Ульянова, д. 11.

eLibrary SPIN: 5172-6651

Mariya M. Kalandiya - PhD student.

11 Dm. Ulyanova street, 117036 Moscow.

eLibrary SPIN: 5172-6651

marika525@mail.ruhttps://orcid.org/0000-0003-2474-9924ТокмаковаА. Ю.TokmakovaA. Yu.

Токмакова Алла Юрьевна - доктор медицинских наук.

117036, Москва, ул. Дм. Ульянова, д. 11.

eLibrary SPIN: 7479-7043

Alla Yu. Tokmakova - MD, PhD.

11 Dm. Ulyanova street, 117036 Moscow.

eLibrary SPIN: 7479-7043

alla-tokmakova@yandex.ruhttps://orcid.org/0000-0001-6581-4521ГалстянГ. Р.GalstyanG. R.

Галстян Гагик Радикович - доктор медицинских наук, профессор.

117036, Москва, ул. Дм. Ульянова, д. 11.

eLibrary SPIN: 9815-7509

Gagik R. Galstyan - MD, PhD, Professor.

11 Dm. Ulyanova street, 117036 Moscow.

eLibrary SPIN: 9815-7509

galstyangagik964@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation20210407202167349Copyright © Каландия М.М., Токмакова А.Ю., Галстян Г.Р., 20212021Каландия М.М., Токмакова А.Ю., Галстян Г.Р.Kalandiya M.M., Tokmakova A.Y., Galstyan G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/12778

Диабетическая нейроостеоартропатия (ДНОАП, стопа Шарко) является серьезным осложнением сахарного диабета, генез которого не окончательно изучен. Данная патология в большинстве случаев поздно диагностируется, что приводит к развитию тяжелых деформаций стопы вплоть до потери опороспособности конечности. Не существует единственной гипотезы формирования стопы Шарко, но есть факторы, предрасполагающие к ее развитию, а также ряд вероятных провоцирующих событий. Избыточное образование и накопление конечных продуктов гликирования (КПГ) может играть важную роль в патогенезе этого осложнения СД. КПГ — различные соединения, образующиеся в результате реакции между углеводами и свободными аминогруппами белков, липидов и нуклеиновых кислот без участия ферментов. Существуют различные факторы, которые приводят к накоплению КПГ в организме человека. Выделяют эндогенные и экзогенные факторы. К первым относятся определенные заболевания, такие как сахарный диабет, почечная недостаточность, ускоряющие процессы гликирования. К экзогенным факторам, приводящим к образованию продуктов липоокисления и гликоокисления, относятся табачный дым и длительная термическая обработка пищи.

В данном обзоре представлена информация о роли КПГ в развитии и прогрессировании осложнений у пациентов с сахарным диабетом.

Diabetic neuroarthropathy (DNOAP, Charcot’s foot) is a serious complication of diabetes mellitus, the genesis of which is not fully understood. In most cases, this pathology is diagnosed late, which leads to the development of severe deformities of the foot, up to the loss of support ability of the limb. There is no single hypothesis for the formation of Charcot’s foot, but there are factors predisposing to its development, as well as a few likely provoking events. Excessive formation and accumulation of end products of glycation may play an important role in the pathogenesis of this complication of diabetes. End products of glycation (AGE) are a variety of compounds formed as a result of a non-enzymatic reaction between carbohydrates and free amino groups of proteins, lipids and nucleic acids. There are various factors that lead to the accumulation of AGE in the human body. Allocate endogenous and exogenous factors. The former include certain diseases, such as diabetes mellitus, renal failure, which accelerate glycation processes. Exogenous factors leading to the formation of lipo-oxidation and glyco-oxidation products include tobacco smoke and prolonged heat treatment of food.

This review provides information on the role of glycation end products in the development and progression of complications in patients with diabetes mellitus.

сахарный диабетстопа ШаркоДНОАПостеоартропатияконечные продукты гликированияdiabetes mellitusCharcot footDNOAPosteoarthropathyadvanced glycation end productsReferencesCho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281. doi: https://doi.org/10.1016/j.diabres.2018.02.023Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281. doi: https://doi.org/10.1016/j.diabres.2018.02.023Токмакова А.Ю., Доронина Л.П., Галстян Г.Р., Сенюшкина Е.С., Митиш В.А. Отдаленные результаты комплексной терапии больной сахарным диабетом 2 типа и двусторонней нейроостеоартропатией. Раны и раневые инфекции // Журнал им. проф. Б.М. Костюченка. — 2018. — Т. 5. — №1. С. 39-49. doi: https://doi.org/10.25199/2408-9613-2018-5-1-39–49Tokmakova AY, Doronina LP, Galstyan GR, Senyushkina ES, Mitish VA. The complex therapy long-term results for patients with the 2nd degree diabetes and the bilateral neuroosteoarthropathy. Wounds and Wound Infections. The Prof. B. M. Kostyuchenok Journal. 2018;5(1):39-49. (in Russ.). doi: https://doi.org/10.25199/2408-9613-2018-5-1-39–49Tesfaye S, Selvarajah D, Gandhi R, et al. Diabetic peripheral neuropathy may not be as its name suggests: Evidence from magnetic resonance imaging. Pain. 2016;157:S72-S80. doi: https://doi.org/10.1097/j.pain.0000000000000465Tesfaye S, Selvarajah D, Gandhi R, et al. Diabetic peripheral neuropathy may not be as its name suggests: Evidence from magnetic resonance imaging. Pain. 2016;157: S72-S80. doi: https://doi.org/10.1097/j.pain.0000000000000465Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: The Monica/Kora Augsburg surveys S2 and S3. Diabetes Care. 2008;31(3):464-469. doi: https://doi.org/10.2337/dc07-1796Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: The Monica/Kora Augsburg surveys S2 and S3. Diabetes Care. 2008;31(3):464-469. doi: https://doi.org/10.2337/dc07-1796Callaghan BC, Xia R, Banerjee M, et al. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016;39(5):801-807. doi: https://doi.org/10.2337/dc16-0081Callaghan BC, Xia R, Banerjee M, et al. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016;39(5):801-807. doi: https://doi.org/10.2337/dc16-0081Lin YC, Lin CSY, Chang TS, et al. Early sensory neurophysiological changes in prediabetes. J Diabetes Investig. 2020;11(2):458-465. doi: https://doi.org/10.1111/jdi.13151Lin YC, Lin CSY, Chang TS, et al. Early sensory neurophysiological changes in prediabetes. J Diabetes Investig. 2020;11(2):458-465. doi: https://doi.org/10.1111/jdi.13151Bongaerts BWC, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36(5):1141-6. doi: https://doi.org/10.2337/dc12-0744Bongaerts BWC, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36(5):1141-6. doi: https://doi.org/10.2337/dc12-0744Kurisu S, Sasaki H, Kishimoto S, et al. Clinical polyneuropathy does not increase with prediabetes or metabolic syndrome in the Japanese general population. J Diabetes Investig. 2019;10(6):1565-1575. doi: https://doi.org/10.1111/jdi.13058Kurisu S, Sasaki H, Kishimoto S, et al. Clinical polyneuropathy does not increase with prediabetes or metabolic syndrome in the Japanese general population. J Diabetes Investig. 2019;10(6):1565-1575. doi: https://doi.org/10.1111/jdi.13058Kloska A, Korzon-Burakowska A, Malinowska M, et al. The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy. Diabetes Res Clin Pract. 2020;166. doi: https://doi.org/10.1016/j.diabres.2020.108337Kloska A, Korzon-Burakowska A, Malinowska M, et al. The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy. Diabetes Res Clin Pract. 2020;166. doi: https://doi.org/10.1016/j.diabres.2020.108337Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123-2129. doi: https://doi.org/10.2337/dc11-0844Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123-2129. doi: https://doi.org/10.2337/dc11-0844Armstrong DG, Peters EJG. Charcot’s arthropathy of the foot. J Am Podiatr Med Assoc. 2002;92(7):390-394. doi: https://doi.org/10.7547/87507315-92-7-390Armstrong DG, Peters EJG. Charcot’s arthropathy of the foot. J Am Podiatr Med Assoc. 2002;92(7):390-394. doi: https://doi.org/10.7547/87507315-92-7-390Frykberg RG, Belczyk R. Epidemiology of the Charcot Foot. Clin Podiatr Med Surg. 2008;25(1):17-28. doi: https://doi.org/10.1016/j.cpm.2007.10.001Frykberg RG, Belczyk R. Epidemiology of the Charcot Foot. Clin Podiatr Med Surg. 2008;25(1):17-28. doi: https://doi.org/10.1016/j.cpm.2007.10.001Salini D, Harish K, Minnie P, et al. Prevalence of Charcot arthropathy in Type 2 diabetes patients aged over 50 years with severe peripheral neuropathy: A retrospective study in a Tertiary Care South Indian Hospital. Indian J Endocrinol Metab. 2018;22(1):107-111. doi: https://doi.org/10.4103/ijem.IJEM_257_17Salini D, Harish K, Minnie P, et al. Prevalence of Charcot arthropathy in Type 2 diabetes patients aged over 50 years with severe peripheral neuropathy: A retrospective study in a Tertiary Care South Indian Hospital. Indian J Endocrinol Metab. 2018;22(1):107-111. doi: https://doi.org/10.4103/ijem.IJEM_257_17Miller DS, William Miller WF. Lichtman,Diabetic neuropathic arthropathy of feet. Published online 1965: 530.Miller DS, William Miller WF. Lichtman,Diabetic neuropathic arthropathy of feet. Published online 1965: 530.McEwen LN, Ylitalo KR, Herman WH, Wrobel JS. Prevalence and risk factors for diabetes-related foot complications in Translating Research into Action for Diabetes (TRIAD).J.Diabetes.Complications.2013;27(6):588-592. doi: https://doi.org/10.1016/j.jdiacomp.2013.08.003McEwen LN, Ylitalo KR, Herman WH, Wrobel JS. Prevalence and risk factors for diabetes-related foot complications in Translating Research into Action for Diabetes (TRIAD). J.Diabetes. Complications.2013;27(6):588-592. doi: https://doi.org/10.1016/j.jdiacomp.2013.08.003Younis B Bin, Shahid A, Arshad R, et al. Charcot osteoarthropathy in type 2 diabetes persons presenting to specialist diabetes clinic at a tertiary care hospital. BMC Endocr Disord. 2015;15(1):1-5. doi: https://doi.org/10.1186/s12902-015-0023-4Younis B Bin, Shahid A, Arshad R, et al. Charcot osteoarthropathy in type 2 diabetes persons presenting to specialist diabetes clinic at a tertiary care hospital. BMC Endocr Disord. 2015;15(1):1-5. doi: https://doi.org/10.1186/s12902-015-0023-4Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366(9502):2058-2061. doi: https://doi.org/10.1016/S0140-6736(05)67029-8Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366(9502):2058-2061. doi: https://doi.org/10.1016/S0140-6736(05)67029-8Baker N, Green A, Krishnan S, et al. Microvascular and C-fiber function in diabetic charcot neuroarthropathy and diabetic peripheral neuropathy. Diabetes Care. 2007;30(12):3077-3079. doi: https://doi.org/10.2337/dc07-1063Baker N, Green A, Krishnan S, et al. Microvascular and C-fiber function in diabetic charcot neuroarthropathy and diabetic peripheral neuropathy. Diabetes Care. 2007;30(12):3077-3079. doi: https://doi.org/10.2337/dc07-1063Trieb K. The Charcot foot: Pathophysiology, diagnosis and classification. Bone Jt J. 2016;98-B(9):1155-1159. doi: https://doi.org/10.1302/0301-620X.98B9.37038Trieb K. The Charcot foot: Pathophysiology, diagnosis and classification. Bone Jt J. 2016;98-B(9):1155-1159. doi: https://doi.org/10.1302/0301-620X.98B9.37038Jansen RB, Christensen TM, Bülow J, et al. Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot. J Diabetes Res. 2018;2018. doi: https://doi.org/10.1155/2018/5647981Jansen RB, Christensen TM, Bülow J, et al. Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot. J Diabetes Res. 2018;2018. doi: https://doi.org/10.1155/2018/5647981Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-508. doi: https://doi.org/10.1378/chest.118.2.503Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-508. doi: https://doi.org/10.1378/chest.118.2.503GROSE SWAR. Regulation of wound healing by growth factors and cytokines. Wound Heal Process Phases Promot. Published online 2003:73-93.GROSE SWAR. Regulation of wound healing by growth factors and cytokines. Wound Heal Process Phases Promot. Published online 2003:73-93.Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139-146. doi: https://doi.org/10.1016/j.abb.2008.03.018Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139-146. doi: https://doi.org/10.1016/j.abb.2008.03.018Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol (Madr). 2007;46(2):221-229. doi: https://doi.org/10.1080/02841860600635870Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol (Madr). 2007;46(2):221-229. doi: https://doi.org/10.1080/02841860600635870Silva I, Branco JC. Rank/RANKL/OPG: Literature review. Acta Reumatol Port. 2011;36(3):209-218.Silva I, Branco JC. Rank/RANKL/OPG: Literature review. Acta Reumatol Port. 2011;36(3):209-218.Mascarenhas JV, Jude EB. The Charcot Foot as a Complication of Diabetic Neuropathy. Curr Diab Rep. 2014;14(12):1-9. doi: https://doi.org/10.1007/s11892-014-0561-6Mascarenhas JV, Jude EB. The Charcot Foot as a Complication of Diabetic Neuropathy. Curr Diab Rep. 2014;14(12):1-9. doi: https://doi.org/10.1007/s11892-014-0561-6Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res. 2004;95(3):233-238. doi: https://doi.org/10.1161/01.RES.0000137876.28454.64Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res. 2004;95(3):233-238. doi: https://doi.org/10.1161/01.RES.0000137876.28454.64Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease. Drugs. 2004;64(5):459-470. doi: https://doi.org/10.2165/00003495-200464050-00001Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease. Drugs. 2004;64(5):459-470. doi: https://doi.org/10.2165/00003495-200464050-00001Bastien P. Aged Human Skin is More Susceptible than Young Skin to Accumulate Advanced Glycoxidation Products Induced by Sun Exposure. J Aging Sci. 2013;01(03):1-5. doi: https://doi.org/10.4172/2329-8847.1000112Bastien P. Aged Human Skin is More Susceptible than Young Skin to Accumulate Advanced Glycoxidation Products Induced by Sun Exposure. J Aging Sci. 2013;01(03):1-5. doi: https://doi.org/10.4172/2329-8847.1000112Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review. Mol Med. 2018;24(1):1-12. doi: https://doi.org/10.1186/s10020-018-0060-3Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review. Mol Med. 2018;24(1):1-12. doi: https://doi.org/10.1186/s10020-018-0060-3Koyama Y, Takeishi Y, Arimoto T, et al. High Serum Level of Pentosidine, an Advanced Glycation End Product (AGE), is a Risk Factor of Patients with Heart Failure. J Card Fail. 2007;13(3):199-206. doi: https://doi.org/10.1016/j.cardfail.2006.11.009Koyama Y, Takeishi Y, Arimoto T, et al. High Serum Level of Pentosidine, an Advanced Glycation End Product (AGE), is a Risk Factor of Patients with Heart Failure. J Card Fail. 2007;13(3):199-206. doi: https://doi.org/10.1016/j.cardfail.2006.11.009Bidasee KR, Zhang Y, Shao CH, et al. Diabetes Increases Formation of Advanced Glycation End Products on Sarco(endo)plasmic Reticulum Ca2+-ATPase. Diabetes. 2004;53(2):463-473. doi: https://doi.org/10.2337/diabetes.53.2.463Bidasee KR, Zhang Y, Shao CH, et al. Diabetes Increases Formation of Advanced Glycation End Products on Sarco(endo)plasmic Reticulum Ca2+-ATPase. Diabetes. 2004;53(2):463-473. doi: https://doi.org/10.2337/diabetes.53.2.463Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med. 2009;11(March):1-13. doi: https://doi.org/10.1017/S146239940900101XYan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med. 2009;11(March):1-13. doi: https://doi.org/10.1017/S146239940900101XPotekhina Y. Collagen Structure and Function. Russ Osteopath J. 2016;(1-2):87-99. doi: https://doi.org/10.32885/2220-0975-2016-1-2-87-99Potekhina Y. Collagen Structure and Function. Russ Osteopath J. 2016;(1-2):87-99. doi: https://doi.org/10.32885/2220-0975-2016-1-2-87-99Bishop JE, Rhodes S, Laurent GJ, Low RB. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Published online 1994:1581-1585.Bishop JE, Rhodes S, Laurent GJ, Low RB. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Published online 1994:1581-1585.Saito M, Soshi S, Fujii K. Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. J Bone Miner Res. 2003;18(9):1695-1705. doi: https://doi.org/10.1359/jbmr.2003.18.9.1695Saito M, Soshi S, Fujii K. Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. J Bone Miner Res. 2003;18(9):1695-1705. doi: https://doi.org/10.1359/jbmr.2003.18.9.1695Shiraki M, Urano T, Kuroda T, et al. The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab. 2008;26(6):595-602. doi: https://doi.org/10.1007/s00774-008-0878-9Shiraki M, Urano T, Kuroda T, et al. The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab. 2008;26(6):595-602. doi: https://doi.org/10.1007/s00774-008-0878-9Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64(11):1043-1053. doi: https://doi.org/10.1507/endocrj.EJ17-0323Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64(11):1043-1053. doi: https://doi.org/10.1507/endocrj.EJ17-0323Portero-otín M, Pamplona R, Ruiz MC, Cabiscol E, Prat J, Bellmunt MJ. Diabetes Induces an Impairment in the Proteolytic Activity Against Oxidized Proteins and a Heterogeneous Effect in Nonenzymatic Protein Modifications in the Cytosol of Rat Liver and Kidney. :2215-2220.Portero-otín M, Pamplona R, Ruiz MC, Cabiscol E, Prat J, Bellmunt MJ. Diabetes Induces an Impairment in the Proteolytic Activity Against Oxidized Proteins and a Heterogeneous Effect in Nonenzymatic Protein Modifications in the Cytosol of Rat Liver and Kidney. :2215-2220.Karim L, Tang SY, Sroga GE, et al. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013;24(9):2441-2447. doi: https://doi.org/10.1007/s00198-013-2319-4Karim L, Tang SY, Sroga GE, et al. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013;24(9):2441-2447. doi: https://doi.org/10.1007/s00198-013-2319-4Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17(10):1514-1523. doi: https://doi.org/10.1007/s00198-006-0155-5Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17(10):1514-1523. doi: https://doi.org/10.1007/s00198-006-0155-5Schwartz A V., Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(7):2380-2386. doi: https://doi.org/10.1210/jc.2008-2498Schwartz A V., Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(7):2380-2386. doi: https://doi.org/10.1210/jc.2008-2498Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26(1):93-100. doi: https://doi.org/10.1007/s00774-007-0784-6Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26(1):93-100. doi: https://doi.org/10.1007/s00774-007-0784-6Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013-1019. doi: https://doi.org/10.1210/jc.2007-1270Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013-1019. doi: https://doi.org/10.1210/jc.2007-1270Farlay D, Armas LAG, Gineyts E, et al. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone from Fractured Patients with Type 1 Diabetes Mellitus. J Bone Miner Res. 2016;31(1):190-195. doi: https://doi.org/10.1002/jbmr.2607Farlay D, Armas LAG, Gineyts E, et al. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone from Fractured Patients with Type 1 Diabetes Mellitus. J Bone Miner Res. 2016;31(1):190-195. doi: https://doi.org/10.1002/jbmr.2607Schmidt AM, Yan S Du, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta - Mol Cell Res. 2000;1498(2-3):99-111. doi: https://doi.org/10.1016/S0167-4889(00)00087-2Schmidt AM, Yan S Du, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta - Mol Cell Res. 2000;1498(2-3):99-111. doi: https://doi.org/10.1016/S0167-4889(00)00087-2Lee EJ, Park JH. Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform. 2013;11(4):224. doi: https://doi.org/10.5808/gi.2013.11.4.224Lee EJ, Park JH. Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform. 2013;11(4):224. doi: https://doi.org/10.5808/gi.2013.11.4.224Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2(1):411-429. doi: https://doi.org/10.1016/j.redox.2013.12.016Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2(1):411-429. doi: https://doi.org/10.1016/j.redox.2013.12.016Xue J, Manigrasso M, Scalabrin M, et al. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure. 2016;24(9):1509-1522. doi: https://doi.org/10.1016/j.str.2016.06.021Xue J, Manigrasso M, Scalabrin M, et al. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure. 2016;24(9):1509-1522. doi: https://doi.org/10.1016/j.str.2016.06.021Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.621854Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.621854Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994;91(16):7742-7746. doi: https://doi.org/10.1073/pnas.91.16.7742Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994;91(16):7742-7746. doi: https://doi.org/10.1073/pnas.91.16.7742Nilforoushan D, Gramoun A, Glogauer M, et al. Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion. Nitric Oxide - Biol Chem. 2009;21(1):27-36. doi: https://doi.org/10.1016/j.niox.2009.04.002Nilforoushan D, Gramoun A, Glogauer M, et al. Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion. Nitric Oxide - Biol Chem. 2009;21(1):27-36. doi: https://doi.org/10.1016/j.niox.2009.04.002Nowak WN, Borys S, Kusińska K, et al. Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome. J Diabetes Investig. 2014;5(1):99-107. doi: https://doi.org/10.1111/jdi.12131Nowak WN, Borys S, Kusińska K, et al. Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome. J Diabetes Investig. 2014;5(1):99-107. doi: https://doi.org/10.1111/jdi.12131Hegab Z. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90. doi: https://doi.org/10.4330/wjc.v4.i4.90Hegab Z. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90. doi: https://doi.org/10.4330/wjc.v4.i4.90Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2014;3(2):94-108. doi: https://doi.org/10.1016/j.molmet.2013.11.006Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2014;3(2):94-108. doi: https://doi.org/10.1016/j.molmet.2013.11.006Saremi A, Howell S, Schwenke DC, et al. Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. Diabetes Care. 2017;40(4):591-598. doi: https://doi.org/10.2337/dc16-1875Saremi A, Howell S, Schwenke DC, et al. Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. Diabetes Care. 2017;40(4):591-598. doi: https://doi.org/10.2337/dc16-1875Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108(12):1853-1863. doi: https://doi.org/10.1172/JCI11951Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108(12):1853-1863. doi: https://doi.org/10.1172/JCI11951Rabbani N, Thornalley PJ. Glyoxalase 1 modulation in obesity and diabetes. Antioxidants Redox Signal. 2019;30(3):354-374. doi: https://doi.org/10.1089/ars.2017.7424Rabbani N, Thornalley PJ. Glyoxalase 1 modulation in obesity and diabetes. Antioxidants Redox Signal. 2019;30(3):354-374. doi: https://doi.org/10.1089/ars.2017.7424Giacco F, Du X, D’Agati VD, et al. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes. 2014;63(1):291-299. doi: https://doi.org/10.2337/db13-0316Giacco F, Du X, D’Agati VD, et al. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes. 2014;63(1):291-299. doi: https://doi.org/10.2337/db13-0316

The authors declare that there are no conflicts of interest present.